DK2742515T3 - Medicinsk indretning, der omfatter agglomererede magnetiske alkoxysilanovertrukne nanopartikler - Google Patents
Medicinsk indretning, der omfatter agglomererede magnetiske alkoxysilanovertrukne nanopartikler Download PDFInfo
- Publication number
- DK2742515T3 DK2742515T3 DK12748166.1T DK12748166T DK2742515T3 DK 2742515 T3 DK2742515 T3 DK 2742515T3 DK 12748166 T DK12748166 T DK 12748166T DK 2742515 T3 DK2742515 T3 DK 2742515T3
- Authority
- DK
- Denmark
- Prior art keywords
- nanoparticles
- medical device
- iron
- suspension
- metal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01F—MAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
- H01F1/00—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01F—MAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
- H01F1/00—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
- H01F1/0036—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties showing low dimensional magnetism, i.e. spin rearrangements due to a restriction of dimensions, e.g. showing giant magnetoresistivity
- H01F1/0045—Zero dimensional, e.g. nanoparticles, soft nanoparticles for medical/biological use
- H01F1/0054—Coated nanoparticles, e.g. nanoparticles coated with organic surfactant
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01F—MAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
- H01F41/00—Apparatus or processes specially adapted for manufacturing or assembling magnets, inductances or transformers; Apparatus or processes specially adapted for manufacturing materials characterised by their magnetic properties
- H01F41/14—Apparatus or processes specially adapted for manufacturing or assembling magnets, inductances or transformers; Apparatus or processes specially adapted for manufacturing materials characterised by their magnetic properties for applying magnetic films to substrates
- H01F41/16—Apparatus or processes specially adapted for manufacturing or assembling magnets, inductances or transformers; Apparatus or processes specially adapted for manufacturing materials characterised by their magnetic properties for applying magnetic films to substrates the magnetic material being applied in the form of particles, e.g. by serigraphy, to form thick magnetic films or precursors therefor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nanotechnology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Power Engineering (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Inorganic Chemistry (AREA)
- Optics & Photonics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Manufacturing & Machinery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compounds Of Iron (AREA)
- Soft Magnetic Materials (AREA)
- Hard Magnetic Materials (AREA)
- Electrotherapy Devices (AREA)
- Powder Metallurgy (AREA)
- Manufacture Of Metal Powder And Suspensions Thereof (AREA)
Claims (19)
1. Medicinsk indretning, der omfatter en suspension af agglomerater af magnetiske alkoxysilanovertrukne metalholdige nanopartikler, der kan opnås ved en fremgangsmåde, hvor en vandig suspension af magnetiske metalnanopartikler inkuberes med alkoxysilan, hvilken medicinske indretning er kendetegnet ved, at inkubationen udføres i fravær af et tilsat organisk opløsningsmiddel, alkoxysilanen er trialkoxysilan, og der tilsættes 0,3 til 0,6 x 10' 3 mol trialkoxysilan pr. 0,9 mol metal.
2. Medicinsk indretning ifølge krav 1, hvor metalnanopartiklerne omfatter jern, jernkompleksforbindelser, jemcarbonylforbindelser eller jernsalte, fortrinsvis jernsalte, især hvor jemsaltet er et jemoxid, fortrinsvis magnetit og/eller maghemit.
3. Den medicinske indretning ifølge krav 2, hvor den vandige suspension af jemoxidnanopartikler i fremgangsmåden a) tilvejebringes ved præcipitation af en opløsning indeholdende en blanding af jern(lll)chlorid og jern(ll)chiorid med natriumhydroxid eller b) ved termisk nedbrydning af et jemsalt eller en jemkompleksforbindelse.
4. Den medicinske indretning ifølge et hvilket som helst af kravene 1 til 3, hvor de magnetiske metalnanopartikler i fremgangsmåden behandles med H2O2 inden inkubationen.
5. Den medicinske indretning ifølge et hvilket som helst af kravene 1 til 4, hvor trialkoxysilanen i fremgangsmåden er valgt fra gruppen bestående af 3-(2-aminoethy!amino)-propyitrimethoxysilan, 3-aminopropyitriethoxysilan, trimethoxysilyipropyl-diethylenetriamin og N-(6-aminohexyl)-3-aminopropyitrimethoxysilan, især3-(2-aminoethylamino)-propyltrimethoxysilan.
6. Den medicinske indretning ifølge et hvilket som helst af kravene 1 til 5, hvor der i fremgangsmåden tilsættes 0,4 til 0,5 x 10-3 mol, fortrinsvis 0,43 ti! 0,45 x 10‘3 mol trialkoxysilan pr. 0,9 mol metal.
7. Den medicinske indretning ifølge et hvilket som helst af kravene 1 til 6, hvor de magnetiske metalnanopartikler i fremgangsmåden opløses inden inkubationen med aikoxysilan.
8. Den medicinske indretning ifølge et hvilket som helst af kravene 1 til 7, hvilken medicinske indretning i fremgangsmåden yderligere omfatter det trin, at de magnetiske nanopartikler opløses efter påbegyndelse af inkubationen med aikoxysilan.
9. Den medicinske indretning ifølge krav 7 eller 8, hvor agglomerateme i fremgangsmåden opløses, indtil der er opnået en gennemsnitlig størrelse på 30 til 450 nm, fortrinsvis på 50 til 350 nm og især på 70 til 300 nm som bestemt ved lysspredning.
10. Den medicinske indretning ifølge et hvilket som helst af kravene 1 til 9, hvor suspensionen af agglomerater koncentreres til en koncentration på mindst cirka 2 M, fortrinsvis på mindst cirka 3 M, mere fortrinsvis på mindst cirka 4 M, endnu mere fortrinsvis på mindst cirka 5 M og især på mindst cirka 6 M som bestemt ved metalindholdet.
11. Den medicinske indretning ifølge et hvilket som helst af kravene 1 til 10, hvor agglomerateme har en gennemsnitlig størrelse på 30 til 450 nm, fortrinsvis på 50 til 350 nm og især på 70 til 300 nm som bestemt ved lysspredning, og hvor metalnanopartiklernes zeta-potential er 25 til 80 mV ved pH 5,2 og en konduktivitet på 2,0 mS/cm.
12. Den medicinske indretning ifølge krav 11, hvor metalnanopartiklerne har en metalkerne med en størrelse på 5 til 25 nm, fortrinsvis 7 til 20 nm og især 9 til 15 nm som bestemt ved elektronmikroskopi.
13. Den medicinske indretning ifølge et hvilket som helst af kravene 11 til 12, hvor metalnanopartiklemes zeta-potential er 35 til 70 mV, især 45 til 60 mV, ved pH 5,2 og en konduktivitet på 2,0 mS/cm.
14. Den medicinske indretning ifølge et hvilket som helst af kravene 11 til 13, hvor agglomeraterne suspenderes i en vandbaseret fysiologisk acceptabel buffer, fortrinsvis hvor nanopartiklerne har en koncentration på mindst cirka 2 M, fortrinsvis på mindst cirka 3 M, mere fortrinsvis på mindst cirka 4 M, mere fortrinsvis på mindst cirka 5 M og især på mindst cirka 6 M som bestemt ved metalindhold, eller fortrinsvis hvor suspensionens viskositet ved en forskydningshastighed på 100/s er Sig med eller mere end 0,005 Pa.s, fortrinsvis lig med eller mere end 0,01 Pa.s, mere fortrinsvis lig med eller mere end 0,1 Pa.s og især lig med eller mere end 1 Pa.s som bestemt ved rotationsreometri.
15. Den medicinske indretning ifølge krav 14, hvor den specifikke absorptionshastighed (SAR) for nanopartiklerne i suspension er større end eller lig med 2 W/g Me, fortrinsvis større end eller lig med 3 W/g Me og især 4 til 12 W/g Me som bestemt ved en magnetisk feltstyrke på 3,5 kA/m og en frekvens på 100 kHz.
16. Den medicinske indretning ifølge krav 14 eller 15, hvor der efter injektion af suspensionen i en isogen tumormodel på eller efter dag 7 efter injektionen fortsat er mindst 90 %, fortrinsvis mindst 93 %, mere fortrinsvis mindst 95 % og især mindst 98 % af det anvendte metal i den injicerede tumor.
17. Medikament, der omfatter suspensionen ifølge krav 1.
18. Suspensionen ifølge krav 1 til anvendelse i en fremgangsmåde til behandling eller forebyggelse af proliferativ sygdom, cancer, tumorer, rheumatisme, arthritis, arthrose og bakterieinfektioner hos en patient.
19. Suspensionen til anvendelse i en fremgangsmåde ifølge krav 18, hvor fremgangsmåden desuden omfatter, at patienten eksponeres for et skiftende magnetfelt.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161522217P | 2011-08-10 | 2011-08-10 | |
PCT/EP2012/003381 WO2013020701A2 (en) | 2011-08-10 | 2012-08-07 | Agglomerating magnetic alkoxysilane-coated nanoparticles |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2742515T3 true DK2742515T3 (da) | 2016-06-13 |
Family
ID=46690467
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12748166.1T DK2742515T3 (da) | 2011-08-10 | 2012-08-07 | Medicinsk indretning, der omfatter agglomererede magnetiske alkoxysilanovertrukne nanopartikler |
Country Status (21)
Country | Link |
---|---|
US (2) | US9408912B2 (da) |
EP (2) | EP3038115B1 (da) |
JP (1) | JP5844902B2 (da) |
KR (1) | KR101513841B1 (da) |
CN (1) | CN104620334B (da) |
AU (1) | AU2012292554B2 (da) |
BR (1) | BR112014002726A8 (da) |
CA (1) | CA2844774C (da) |
CL (1) | CL2014000298A1 (da) |
CO (1) | CO6940414A2 (da) |
DE (1) | DE202012012795U1 (da) |
DK (1) | DK2742515T3 (da) |
ES (2) | ES2582283T3 (da) |
HK (1) | HK1210317A1 (da) |
IL (1) | IL230799A (da) |
MX (1) | MX358576B (da) |
PL (2) | PL2742515T3 (da) |
PT (1) | PT2742515T (da) |
RU (1) | RU2622025C2 (da) |
WO (1) | WO2013020701A2 (da) |
ZA (1) | ZA201400564B (da) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10513616B2 (en) | 2014-06-06 | 2019-12-24 | The Regents Of The University Of California | Sunlight reflecting materials and methods of fabrication |
WO2021152136A1 (en) | 2020-01-31 | 2021-08-05 | Magforce Ag | Paste comprising magnetic alkoxysilane-coated metal containing nanoparticles |
DE102020116859A1 (de) | 2020-06-26 | 2021-12-30 | Pharma Development Holding Gmbh | Liposomen |
KR102503870B1 (ko) * | 2021-01-08 | 2023-02-24 | 한밭대학교 산학협력단 | 온열치료용 산화철 나노 클러스터 및 이의 제조 방법 |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3945945A (en) | 1971-05-10 | 1976-03-23 | Norton Company | High surface area alumina bodies |
DE2543962A1 (de) | 1975-10-02 | 1977-04-14 | Dynamit Nobel Ag | Verbesserte eisenoxid-magnetpigmente fuer die herstellung von magnetschichten |
US4169912A (en) | 1975-10-02 | 1979-10-02 | Dynamit Nobel Aktiengesellschaft | Iron oxide magnetic pigments for the production of magnetic coatings |
CA1254238A (en) | 1985-04-30 | 1989-05-16 | Alvin P. Gerk | Process for durable sol-gel produced alumina-based ceramics, abrasive grain and abrasive products |
US5597531A (en) * | 1985-10-04 | 1997-01-28 | Immunivest Corporation | Resuspendable coated magnetic particles and stable magnetic particle suspensions |
US4827945A (en) | 1986-07-03 | 1989-05-09 | Advanced Magnetics, Incorporated | Biologically degradable superparamagnetic materials for use in clinical applications |
FR2618084B1 (fr) | 1987-07-15 | 1989-11-10 | Rhone Poulenc Chimie | Microspheres magnetisables a base de polysiloxane, leur procede de preparation et leur application en biologie |
DE68926708T2 (de) | 1988-08-04 | 1996-10-31 | Advanced Magnetics Inc | Von einem rezeptor induziertes kontrastmittel für den endocytose-typ mri |
KR970011315B1 (ko) | 1988-10-13 | 1997-07-09 | 아이. 씨. 아이 오스트레일리아 오퍼레이션스 프러프라이어터리 리미티드 | 압분용 세라믹 분말 및 그 제조방법 |
US5460831A (en) | 1990-06-22 | 1995-10-24 | The Regents Of The University Of California | Targeted transfection nanoparticles |
US5462751A (en) | 1990-06-22 | 1995-10-31 | The Regeants Of The University Of California | Biological and pharmaceutical agents having a nanomeric biodegradable core |
DE4026978A1 (de) | 1990-08-25 | 1992-02-27 | Bayer Ag | Auf traegern angebrachte ein- oder mehrlagige schichtelemente und ihre herstellung |
US5616311A (en) | 1991-01-15 | 1997-04-01 | Hemosphere, Inc. | Non-crosslinked protein particles for therapeutic and diagnostic use |
JP3389611B2 (ja) | 1992-02-28 | 2003-03-24 | 戸田工業株式会社 | 無機物粒子含有樹脂複合球状物粉体 |
DE4212633A1 (de) | 1992-04-15 | 1993-10-21 | Inst Neue Mat Gemein Gmbh | Verfahren zur Herstellung oberflächenmodifizierter nanoskaliger keramischer Pulver |
ATE207727T1 (de) | 1992-05-29 | 2001-11-15 | Univ California | Beschichtetes transplantat sowie herstellungsverfahren dafür |
ES2176209T3 (es) | 1992-11-06 | 2002-12-01 | Hisamitsu Pharmaceutical Co | Preparacion farmaceutica oral liberable en el tracto digestivo inferior. |
US5401313A (en) | 1993-02-10 | 1995-03-28 | Harcros Pigments, Inc. | Surface modified particles and method of making the same |
US5916539A (en) | 1993-03-02 | 1999-06-29 | Silica Gel Ges. M.B.H. | Superparamagnetic particles, process for producing the same and their use |
JPH06270155A (ja) | 1993-03-23 | 1994-09-27 | Sekisui Chem Co Ltd | 型内被覆用樹脂組成物 |
US5547748A (en) | 1994-01-14 | 1996-08-20 | Sri International | Carbon nanoencapsulates |
FR2721615A1 (fr) | 1994-06-24 | 1995-12-29 | Rhone Poulenc Chimie | Procédé de préparation de particules d'oxyde métallique organophiles. |
JPH10502494A (ja) | 1994-07-07 | 1998-03-03 | チロン ダイアグノスティクス コーポレーション | 高分散性の磁性金属酸化物、その製造方法および使用 |
ATE191086T1 (de) | 1994-07-27 | 2000-04-15 | Pilgrimm Herbert | Superparamagnetische teilchen, verfahren zur herstellung und deren verwendung |
US6103379A (en) | 1994-10-06 | 2000-08-15 | Bar-Ilan University | Process for the preparation of microspheres and microspheres made thereby |
GB9420390D0 (en) | 1994-10-10 | 1994-11-23 | Nycomed Salutar Inc | Liposomal agents |
US5540959A (en) | 1995-02-21 | 1996-07-30 | Howard J. Greenwald | Process for preparing a coated substrate |
DE19515820A1 (de) | 1995-04-29 | 1996-10-31 | Inst Neue Mat Gemein Gmbh | Verfahren zur Herstellung schwach agglomerierter nanoskaliger Teilchen |
JPH09646A (ja) | 1995-06-16 | 1997-01-07 | Toshiba Corp | 治療用誘導加熱装置 |
US6022500A (en) | 1995-09-27 | 2000-02-08 | The United States Of America As Represented By The Secretary Of The Army | Polymer encapsulation and polymer microsphere composites |
US5695900A (en) * | 1995-12-21 | 1997-12-09 | Colorado School Of Mines | Surface treatment of magnetic particles for use in reprographic processes |
US5922403A (en) | 1996-03-12 | 1999-07-13 | Tecle; Berhan | Method for isolating ultrafine and fine particles |
DE19612001A1 (de) | 1996-03-18 | 1997-09-25 | Silica Gel Gmbh Adsorptions Te | Superparamagnetische Teilchen mit vergrößerter R¶1¶-Relaxivität, Verfahren zur Herstellung und deren Verwendung |
DE19614136A1 (de) | 1996-04-10 | 1997-10-16 | Inst Neue Mat Gemein Gmbh | Verfahren zur Herstellung agglomeratfreier nanoskaliger Eisenoxidteilchen mit hydrolysebeständigem Überzug |
US5922537A (en) | 1996-11-08 | 1999-07-13 | N.o slashed.AB Immunoassay, Inc. | Nanoparticles biosensor |
EP0971692B1 (de) | 1997-03-07 | 2003-03-05 | Max-Delbrück-Centrum Für Molekulare Medizin | Spezifische magnetosomen, verfahren zu ihrer herstellung und ihre verwendung |
DE19716732C2 (de) | 1997-03-07 | 1999-03-25 | Max Delbrueck Centrum | Spezifische Magnetosomen, Verfahren zu ihrer Herstellung und ihre Verwendung |
WO1998052992A1 (de) * | 1997-05-23 | 1998-11-26 | Bayer Aktiengesellschaft | Organosilan-oligomere |
DE19726282A1 (de) | 1997-06-20 | 1998-12-24 | Inst Neue Mat Gemein Gmbh | Nanoskalige Teilchen mit einem von mindestens zwei Schalen umgebenen eisenoxid-haltigen Kern |
DE19912502A1 (de) | 1999-03-19 | 2000-09-21 | Inst Neue Mat Gemein Gmbh | Nanoskalige Teilchen, Komplexe mit Polynukleotiden und deren Verwendung |
DE19921088C2 (de) | 1999-04-30 | 2003-08-07 | Magforce Applic Gmbh | Stent zur Offenhaltung gangartiger Strukturen |
DE19940220B4 (de) | 1999-08-19 | 2007-05-03 | Magforce Nanotechnologies Ag | Medizinisches Präparat zur Behandlung von Arthrose, Arthritis und anderen rheumatischen Gelenkerkrankungen |
US6548264B1 (en) | 2000-05-17 | 2003-04-15 | University Of Florida | Coated nanoparticles |
AU2002320058A1 (en) | 2001-06-06 | 2002-12-16 | The General Hspital Corporation | Magnetic-nanoparticle conjugates and methods of use |
US7731648B2 (en) | 2001-07-25 | 2010-06-08 | Aduro Biotech | Magnetic nanoscale particle compositions, and therapeutic methods related thereto |
US20040156852A1 (en) | 2003-02-06 | 2004-08-12 | Triton Biosystems, Inc. | Therapy via targeted delivery of nanoscale particles |
DE10153639A1 (de) * | 2001-10-31 | 2003-05-22 | Inst Neue Mat Gemein Gmbh | Superparamagnetisches Eisenoxid enthaltende Kompositpartikel |
DE10261406A1 (de) | 2002-12-30 | 2004-07-15 | Sustech Gmbh & Co. Kg | Verfahren zur Herstellung oberflächenbeschichteter nanoskaliger Teilchen und von Suspensionen, die diese enthalten |
DE10331439B3 (de) | 2003-07-10 | 2005-02-03 | Micromod Partikeltechnologie Gmbh | Magnetische Nanopartikel mit verbesserten Magneteigenschaften |
US20040156846A1 (en) | 2003-02-06 | 2004-08-12 | Triton Biosystems, Inc. | Therapy via targeted delivery of nanoscale particles using L6 antibodies |
US20050119725A1 (en) | 2003-04-08 | 2005-06-02 | Xingwu Wang | Energetically controlled delivery of biologically active material from an implanted medical device |
FR2855315B1 (fr) | 2003-05-23 | 2005-08-19 | Centre Nat Rech Scient | Ferrofluides stables en milieu neutre et ferrofluides modifies obtenus par modification de la surface des particules de ces ferrofluides |
US8651113B2 (en) | 2003-06-18 | 2014-02-18 | Swr&D Inc. | Magnetically responsive nanoparticle therapeutic constructs and methods of making and using |
US7531149B2 (en) | 2003-10-14 | 2009-05-12 | The Board Of Trustees Of The University Of Arkansas | Synthetic control of metal oxide nanocrystal sizes and shapes |
US20050090732A1 (en) | 2003-10-28 | 2005-04-28 | Triton Biosystems, Inc. | Therapy via targeted delivery of nanoscale particles |
DE102004052533A1 (de) | 2004-10-15 | 2006-05-04 | Mykhaylyk, Olga, Dr. | Magnetische Partikel zur Verwendung in Therapie und Diagnostik |
WO2006057467A1 (en) | 2004-11-26 | 2006-06-01 | Seoul National University Industry Foundation | Method for large-scale production of monodisperse nanoparticles |
US7462446B2 (en) | 2005-03-18 | 2008-12-09 | University Of Washington | Magnetic nanoparticle compositions and methods |
DE102005016873A1 (de) | 2005-04-12 | 2006-10-19 | Magforce Nanotechnologies Ag | Nanopartikel-Wirstoff-Konjugate |
EP1883425A1 (en) | 2005-05-23 | 2008-02-06 | Universite De Geneve | Injectable superparamagnetic nanoparticles for treatment by hyperthermia and use for forming an hyperthermic implant |
GB0512374D0 (en) | 2005-06-17 | 2005-07-27 | Nanosphere Ltd | Coated microspheres |
DE102005039579B4 (de) * | 2005-08-19 | 2022-06-30 | Magforce Ag | Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen |
US20070269380A1 (en) | 2005-10-11 | 2007-11-22 | Washington, University Of | Methotrexate-modified nanoparticles and related methods |
DE102005059751A1 (de) | 2005-12-09 | 2007-06-14 | Ferropharm Gmbh Forschungslabor | Wässrige Dispersion von superparamagnetischen Eindomänenteilchen, deren Herstellung und Verwendung zur Diagnose und Therapie |
JP2008019202A (ja) * | 2006-07-12 | 2008-01-31 | Koichi Jinbo | メラノーマ標的温熱免疫療法治療剤 |
CH697953B1 (fr) | 2006-07-31 | 2010-01-29 | Ecole Polytech | Nanoparticules à noyau métallique recouvert de silice. |
TWI321133B (en) | 2006-08-01 | 2010-03-01 | Univ Kaohsiung Medical | Folate-receptor-targeting iron oxide nanoparticles coated with poly(ethylene glycol) |
RU2373957C2 (ru) | 2006-10-13 | 2009-11-27 | Александр Метталинович Тишин | Носитель для лекарственных средств и биологически активных веществ для лечения и диагностики и применение его для создания лекарственных средств и способа регулируемой управляемой доставки лекарственного средства или биологически активного вещества с регулируемой десорбцией его |
EP1935436A1 (en) | 2006-12-12 | 2008-06-25 | Dublin City University | Nanoparticle clusters and methods for forming same |
JP5057208B2 (ja) * | 2006-12-20 | 2012-10-24 | 株式会社豊田中央研究所 | 磁性材料の製造方法 |
US20110104073A1 (en) | 2007-01-18 | 2011-05-05 | Qi Zeng | Iron/Iron Oxide Nanoparticle and Use Thereof |
EP1952919B1 (en) | 2007-02-02 | 2013-04-24 | FUJIFILM Corporation | Magnetic nanoparticles and aqueous colloid composition containing the same |
BRPI0821856A2 (pt) | 2008-01-04 | 2015-06-16 | Sparkxis B V | Modificação na superfície de nanopartículas de óxido metálico |
DE102008003615A1 (de) * | 2008-01-09 | 2009-07-16 | Magforce Nanotechnologies Ag | Magnetische Transducer |
WO2009094568A1 (en) | 2008-01-23 | 2009-07-30 | The Regents Of The University Of California | Nano-devices having impellers for capture and release of molecules |
DE102008008522A1 (de) | 2008-02-11 | 2009-08-13 | Magforce Nanotechnologies Ag | Implantierbare Nanopartikel-enthaltende Produkte |
US20090226376A1 (en) | 2008-03-05 | 2009-09-10 | General Electric Company | Novel Mixed Ligand Core/Shell Iron Oxide Nanoparticles for Inflammation Imaging |
US20100113861A1 (en) | 2008-10-27 | 2010-05-06 | Board Of Trustees Of The University Of Arkansas | Metallic nanoparticles with coated shells and applications of same |
GB2472446A (en) | 2009-08-07 | 2011-02-09 | Ct Fuer Angewandte Nanotechnologie | Metal oxide particles coated with polyethylene glycol and their synthesis |
DE102009058769A1 (de) | 2009-12-16 | 2011-06-22 | MagForce Nanotechnologies AG, 10589 | Temperaturabhängige Aktivierung von katalytischen Nukleinsäuren zur kontrollierten Wirkstofffreisetzung |
EP2383374A1 (en) | 2010-04-29 | 2011-11-02 | BASF Corporation | Nano-particles containing carbon and a ferromagnetic metal or alloy |
CN103025314A (zh) | 2010-05-26 | 2013-04-03 | 通用医疗公司 | 磁性纳米微粒 |
US20130095043A1 (en) | 2010-06-29 | 2013-04-18 | Koninklijke Philips Electronics N.V. | Synthesis of high-performance iron oxide particle tracers for magnetic particle imaging (mpi) |
TW201247225A (en) | 2011-05-17 | 2012-12-01 | Univ Nat Chiao Tung | Drug carrier with thermal sensitivity, manufacturing method thereof, and use of the same as NMR contrast agent |
US10220004B2 (en) | 2011-07-14 | 2019-03-05 | The Regents Of The University Of California | Method of controlled delivery using sub-micron-scale machines |
-
2012
- 2012-08-07 RU RU2014109015A patent/RU2622025C2/ru active
- 2012-08-07 EP EP16000350.5A patent/EP3038115B1/en active Active
- 2012-08-07 PL PL12748166T patent/PL2742515T3/pl unknown
- 2012-08-07 PT PT127481661T patent/PT2742515T/pt unknown
- 2012-08-07 CN CN201280038864.1A patent/CN104620334B/zh active Active
- 2012-08-07 MX MX2014001186A patent/MX358576B/es active IP Right Grant
- 2012-08-07 CA CA2844774A patent/CA2844774C/en active Active
- 2012-08-07 DE DE202012012795U patent/DE202012012795U1/de not_active Expired - Lifetime
- 2012-08-07 US US13/877,891 patent/US9408912B2/en active Active
- 2012-08-07 ES ES12748166.1T patent/ES2582283T3/es active Active
- 2012-08-07 BR BR112014002726A patent/BR112014002726A8/pt not_active IP Right Cessation
- 2012-08-07 JP JP2014524301A patent/JP5844902B2/ja active Active
- 2012-08-07 PL PL16000350T patent/PL3038115T3/pl unknown
- 2012-08-07 DK DK12748166.1T patent/DK2742515T3/da active
- 2012-08-07 KR KR1020147005840A patent/KR101513841B1/ko active IP Right Grant
- 2012-08-07 AU AU2012292554A patent/AU2012292554B2/en active Active
- 2012-08-07 WO PCT/EP2012/003381 patent/WO2013020701A2/en active Application Filing
- 2012-08-07 ES ES16000350T patent/ES2807209T3/es active Active
- 2012-08-07 EP EP12748166.1A patent/EP2742515B1/en active Active
-
2014
- 2014-01-23 ZA ZA2014/00564A patent/ZA201400564B/en unknown
- 2014-02-03 IL IL230799A patent/IL230799A/en active IP Right Grant
- 2014-02-06 CL CL2014000298A patent/CL2014000298A1/es unknown
- 2014-02-07 CO CO14026546A patent/CO6940414A2/es unknown
-
2015
- 2015-11-05 HK HK15110910.9A patent/HK1210317A1/zh unknown
-
2016
- 2016-06-30 US US15/198,708 patent/US9962442B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kwon et al. | Large‐scale synthesis and medical applications of uniform‐sized metal oxide nanoparticles | |
Patsula et al. | Superparamagnetic Fe3O4 nanoparticles: synthesis by thermal decomposition of iron (III) glucuronate and application in magnetic resonance imaging | |
Ho et al. | Monodisperse magnetic nanoparticles for theranostic applications | |
Piñeiro et al. | Iron oxide based nanoparticles for magnetic hyperthermia strategies in biological applications | |
CN103028116B (zh) | 基于纤维素基模板的磁性纳米复合微球及其制法和用途 | |
Pernal et al. | Hydroxyapatite as a vehicle for the selective effect of superparamagnetic iron oxide nanoparticles against human glioblastoma cells | |
US9962442B2 (en) | Agglomerating magnetic alkoxysilane-coated nanoparticles | |
Zhao et al. | Investigations on the interactions of proteins with polyampholyte-coated magnetite nanoparticles | |
Fuentes-Garcia et al. | Sonochemical route for mesoporous silica-coated magnetic nanoparticles towards pH-triggered drug delivery system | |
Yang et al. | Rational design of GO-modified Fe3O4/SiO2 nanoparticles with combined rhenium-188 and gambogic acid for magnetic target therapy | |
Pourmadadi et al. | Theranostic applications of stimulus-responsive systems based on Fe2O3 | |
Chavan et al. | Magnetic nanoparticles–A new era in nanotechnology | |
Kettering et al. | Characterization of iron oxide nanoparticles adsorbed with cisplatin for biomedical applications | |
Yang et al. | Functionalization of magnetic nanoparticles with organic ligands toward biomedical applications | |
Mdlovu et al. | Preparation and in-vitro/in-vivo evaluation of doxorubicin-loaded magnetic SBA-15 nanocomposites from rice husk for enhancing therapeutic efficacy | |
Kurczewska et al. | Recent progress and challenges regarding magnetite-based nanoparticles for targeted drug delivery | |
Zasońska et al. | Combined antitumor effect of surface-modified superparamagnetic maghemite nanoparticles and a vitamin E derivative on experimental Walker-256 mammary gland carcinosarcoma | |
Liang et al. | Research progress of calcium carbonate nanomaterials in cancer therapy: challenge and opportunity | |
WO2021152136A1 (en) | Paste comprising magnetic alkoxysilane-coated metal containing nanoparticles | |
Thirumurugan et al. | NIR-Responsive Methotrexate-Modified Iron Selenide Nanorods for Synergistic Magnetic Hyperthermic, Photothermal, and Chemodynamic Therapy | |
Joshi et al. | Multifunctional Ultrasmall Theranostic Nanohybrids Developed by Ultrasonic Atomizer for Drug Delivery and Magnetic Resonance Imaging | |
Xiao et al. | Biodegradable Poly (amino acid)–Bismuth Nanotheranostic Agents for CT/MR Imaging and Photothermal–Chemodynamic Synergistic Therapy | |
Kornev et al. | Magnetic Nanoparticles and Intracellular Delivery of Biopolymers | |
Albukhaty et al. | Iron Oxide Nanoparticles: The Versatility of the Magnetic and Functionalized Nanomaterials in Targeting Drugs, and Gene Deliveries with Effectual Magnetofection | |
Etemadi et al. | Magnetic fluid hyperthermia (MFH) based on magnetic nanoparticles (MNPs): Physical characteristics, historical perspective, clinical trials, technological challenges, and recent advances |